Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jasem Al-Hashel is active.

Publication


Featured researches published by Jasem Al-Hashel.


Multiple Sclerosis Journal | 2014

Increasing prevalence and incidence rates of multiple sclerosis in Kuwait

Raed Alroughani; Samar Farouk Ahmed; R. Behbahani; R Khan; Anil Thussu; Kj Alexander; A. Ashkanani; V Nagarajan; Jasem Al-Hashel

Background: Kuwait was considered as low to intermediate risk area for MS. Objectives: To determine the prevalence and incidence rates of MS among Kuwaiti nationals based on 2011 population census. Methods: This cross-sectional study was conducted between October 2010 and April 2013 using the newly developed national MS registry in Kuwait. Patients with a diagnosis of MS according to 2010 revised McDonald criteria were identified. The crude, age- and sex-specific prevalence and incidence rates among Kuwaiti patients were calculated. Results: 1176 MS patients were identified of which 927 (78.8%) were Kuwaitis and 249 (21.2%) were expatriates. Among Kuwaiti patients, female to male ratio was 1.8:1 with a mean age of 35.40 ± 10.99 years. The prevalence rate of MS was 85.05 per 100,000 persons (95% CI: 82.80 – 87.04). There was a peak in prevalence among patients aged 30–39 years. The incidence of MS was 6.88 per 100,000 persons (95% CI 5.52–8.55). Between 2003 and 2011, the incidence increased 3.22 and 2.54 times in women and men respectively. Conclusion: Kuwait is considered a high-risk area for MS. The significant increase in prevalence and incidence rates may represent a true increase despite the improvement in case ascertainment and case definition.


Neuroepidemiology | 2008

The Prevalence of Multiple Sclerosis in the Middle East

Jasem Al-Hashel; Aaron D. Besterman; Christina Wolfson

Background: The prevalence of multiple sclerosis (MS) in the Middle East has been reported to be low to medium. Methods: To verify this assertion we conducted a review of published data on the occurrence of MS in the Middle East.Results: Fourteen studies reporting on the prevalence of MS in the Middle East were initially identified, 5 of which were excluded due to inadequate data or serious methodological limitations. The data from the 9 included studies suggested that the prevalence of MS may vary widely within the Middle East, from low to high. However, these 9 studies were inconsistent in case ascertainment, inclusion criteria and methods of prevalence calculation, and most did not include age/sex standardization. Conclusion: Methodological inconsistencies among studies make it difficult to be confident in drawing conclusions about the prevalence of MS in the Middle East. Nevertheless, there is little evidence to support the assertion that the prevalence of MS in the Middle East is low to medium. Rather, the prevalence of MS in the Middle East may range from low to high, depending on the specific population and environment of study. However, to confirm these findings, further epidemiological research is needed.


International Scholarly Research Notices | 2013

Early versus Late Surgical Treatment for Neurogenic Thoracic Outlet Syndrome

Jasem Al-Hashel; Ashraf Ali M. A. El Shorbgy; Samar Farouk Ahmed; Rawhia R. Elshereef

Objectives. To compare the outcome of early surgical intervention versus late surgical treatment in cases of neurogenic thoracic outlet syndrome (NTOS). Design. Prospective study. Settings. Secondary care (Al-Minia University Hospital, Egypt) from 2007 to 2010. Participants. Thirty-five patients of NTOS (25 women and 10 men, aged 20–52 years), were classified into 2 groups. First group (20 patients) was operated within 3 months of the onset and the second group (15 patients) was operated 6 months after physiotherapy. Interventions. All patients were operated via supraclavicular surgical approach. Outcomes Measures. Both groups were evaluated clinically and, neurophysiologically and answered the disabilities of the arm, shoulder, and hand (DASH) questionnaire preoperatively and 6 months after the surgery. Results. Paraesthesia, pain, and sensory nerve action potential (SNAP) of ulnar nerve were significantly improved in group one. Muscle weakness and denervation in electromyography EMG were less frequent in group one. The postoperative DASH score improved in both groups but it was less significant in group two (P < .001 in group 1 and P < .05 in group 2). Conclusions. Surgical treatment of NTOS improves functional disability and stop degeneration of the nerves. Early surgical treatment decreases the occurrence of muscle wasting and denervation of nerves compared to late surgery.


Muscle & Nerve | 2015

Sonography in carpal tunnel syndrome with normal nerve conduction studies.

Jasem Al-Hashel; Hanaa M. Rashad; Mohamed Ragab Nouh; Hanan A. Amro; Adnan J. Khuraibet; Todor Shamov; Plamen Tzvetanov; Rossen T. Rousseff

We assessed the yield of high‐resolution ultrasonography (HRUS) in patients with clinically definite carpal tunnel syndrome (CTS) and normal nerve conduction studies (NCS).


Journal of the Neurological Sciences | 2015

Incidence and prevalence of pediatric onset multiple sclerosis in Kuwait: 1994-2013.

Raed Alroughani; Saeed Akhtar; Samar Farouk Ahmed; Raed Behbehani; J. Al-Abkal; Jasem Al-Hashel

OBJECTIVES This study aimed to assess the incidence and prevalence of pediatric-onset multiple sclerosis (POMS) along with temporal and gender differentials in these estimates in Kuwait. METHODS We identified MS patients with pediatric (age <18 years) onset between 1994 and 2013 from national MS registry. Year and gender-specific incidence rate and prevalence estimates were computed. Multivariable Poisson regression analyses of time-series cross-sectional panel data were conducted to evaluate temporal and gender related variations in yearly POMS incidence rate and prevalence. RESULTS 122 POMS patients were identified; of which 90 (73.8%) were females. During 2013, POMS incidence rate and prevalence (per 100,000) were 2.1 and 6.0 respectively. Multivariable Poisson regression model revealed statistically significant 5% increase in POMS incidence rate (p=0.002) and 6% increase in prevalence (p<0.001) from 1994 to 2013. Furthermore, during the study period, female children were more likely to have higher POMS incidence rate (relative rate=2.9; p<0.001) and prevalence (prevalence ratio=2.8; p<0.001). CONCLUSIONS The temporal increase and gender disparity in POMS incidence and prevalence corroborate the findings of earlier studies conducted elsewhere. Knowledge of increasing POMS burden may help in optimal planning for better management of patients in the region.


Journal of the Neurological Sciences | 2016

JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study

Raed Alroughani; Saeed Akhtar; Samar Farouk Ahmed; Samia J. Khoury; Jasem Al-Hashel; Mohammad Ali Sahraian; Mohammed Al Jumah; Maya Zeineddine; Sahar Farhat; Hassan Doumiati; Bassem Yamout

OBJECTIVES To estimate JCV seroprevalence and risk of seroconversion against JCV among MS patients in the Middle East. METHODS This multicenter study was conducted by implementing a cross-sectional design to assess JCV seroprevalence, and a longitudinal design to assess the risk of JCV seroconversion. Multivariable logistic and Poisson regression analyses were used to assess the relationship between clinical variables and JCV seropositivity and risk of seroconversion. RESULTS Of 581 MS patients, 64.9% patients were females. Mean age and mean disease duration were 33.9 and 8.4years respectively. JCV seroprevalence was 48.7%. Male gender (p=0.002), age at onset (p=0.001) and disease duration of 20 or more years (p=0.007) were significantly associated with JCV seropositivity. Among patients (n=125), followed longitudinally, the risk of JCV seroconversion was 17.6% (95% CI: 11.4%-25.4%) during a median follow-up of 18months. The proportion of seroreverted and pseudoconverted patients was 4% and 3.2% respectively. CONCLUSIONS JCV seroprevalence among MS patients in the Middle East was lower than international figures. Male gender, age at onset and disease duration were significantly associated with JCV seropositivity. Risk of JCV seroconversion was higher than previously reported figures. Observed JCV sero-reversion or pseudo-conversion entail watchful period before embarking on a clinical decision.


SpringerPlus | 2015

Status migrainosus as an initial presentation of multiple sclerosis

Raed Alroughani; Samar Farouk Ahmed; Riyadh Khan; Jasem Al-Hashel

BackgroundDemyelinating plaques may induce headache through disruption of the pathways, which are implicated in the pathogeneses of migraine. We report a case of 25-year-old female patient, who presented with status migrainosus fulfilling the criteria of international classification of headache disorder. She was eventually diagnosed with multiple sclerosis (MS) after an extensive work-up and long-term clinical and radiological follow-up.FindingsAt the onset of status migrainosus, magnetic resonance imaging (MRI) revealed the presence of several demyelinating lesions fulfilling Swanton criteria. She was started on migraine prophylactic treatment but there was no subsequent response. One year later, she presented with recurrent status migrainosus and a follow-up MRI revealed multiple gadolinium-enhancing lesions in the brain. She was treated with abortive migraine medications. Within the following 2 year, she developed ascending parasthesia and weakness of both lower limbs indicative of incomplete transverse myelitis in association with recurrent status migrainosus. A diagnosis of MS was established based on a follow-up MRI that satisfied the revised 2010 McDonald criteria. Both the headache and neurological signs improved with IV methylprednisolone therapy. Her headache entered remission after initiation of a disease modifying therapy.ConclusionStatus migrainosus can be the initial presentation of MS. Unresponsiveness to migraine prophylactic therapy in the presence of active demyelinating plaque in MRI brain may pose a diagnostic challenge and a diagnosis of MS might be considered.


International Journal of Neuroscience | 2015

Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a nation-wide cohort

Raed Alroughani; Saeed Akhtar; Samar Farouk Ahmed; Jasem Al-Hashel

Background: Predicting disease progression over time is challenging despite the available literature data. Aim: To assess whether baseline clinical variables of MS patients would predict the conversion to progressive phase of the disease. Materials & methods: Utilizing the national MS registry, patients who had relapsing onsets and had confirmed EDSS score at baseline and follow-up visits were included. Primary progressive MS and CIS patients were excluded. Clinical variables (gender, age at onset, disease duration, number of relapses, EDSS score) were collected. The end point was conversion to secondary progressive MS. Chi Square and multivariable logistic regression were used to determine the influence of clinical variables on disease progression. Results: Data of 803 MS patients with relapsing onset were analyzed. Eighty five (10.6%) patients reached the end point. The risk of disease progression was significantly higher in men (p = 0.015), in patients who developed MS ≥ 40 years of age (p = 0.041) and who had ≥ 3 relapses during their disease course (p < 0.001). Spinal cord presentation at onset was predictive of progression (aOR = 2.01; p = 0.06) while optic neuritis at onset was associated with lower risk of progression (aOR = 0.30; p = 0.03). EDSS score at first visit did not influence disease progression when tested at 2 different cutoffs (EDSS < 4 vs. ≥ 4 and EDSS < 6 vs. ≥ 6) using multivariable logistic regression analysis (p = 0.960 and p = 0.866), respectively. Conclusion: Men and patients who presented at age 40 yeas or beyond had increased risk of MS progression. Spinal cord symptoms at onset and 3 or more relapses were predictive of progression.


Medical Principles and Practice | 2013

Unusual Presentation of Guillain-Barré Syndrome following Traumatic Bone Injuries: Report of Two Cases

Jasem Al-Hashel; John K. John; Periasamy Vembu

Objective: To report two cases of Guillain-Barré syndrome (GBS) which occurred following traumatic bone injuries. Presentation and Intervention: Two patients presented with traumatic bone injuries. The first was a 47-year-old female who was admitted with fracture of both tibial bones sustained during a road traffic accident. One week after surgical fixation of the fracture, she developed areflexic weakness of all four limbs and respiratory muscle weakness. The nerve conduction study was consistent with GBS. She was administered intravenous immunoglobulins which was repeated after 2 weeks. She recovered gradually. The second patient was a 31-year-old male who was admitted with 4-days history of severe back pain which occurred when he lifted a heavy weight. He then developed ascending areflexic weakness of all four limbs and bifacial weakness. X-ray and magnetic resonance imaging of the lumbosacral spine revealed fracture of L1 and L2 vertebrae. Nerve conduction studies confirmed the diagnosis of GBS. He was given mechanical ventilatory support and was treated with intravenous immunoglobulins and later plasmapheresis. However, his condition gradually deteriorated as he developed aspiration pneumonia and sepsis with multi-organ failure and finally expired. Conclusion: These cases highlight the importance of considering GBS as a differential diagnosis when patients with traumatic bone injuries develop acute neuromuscular weakness. Early diagnosis and treatment may prevent morbidity and mortality.


Neurology | 2018

Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era

Raed Alroughani; Maryam S. Alowayesh; Samar Farouk Ahmed; Raed Behbehani; Jasem Al-Hashel

Objective To determine the rate of relapse occurrence during pregnancy and postpartum. Methods In a cross-sectional study using the national multiple sclerosis (MS) registry, pregnant women with relapsing MS were identified. Data on demographics, clinical characteristics, and disease-modifying therapies (DMTs), including washout periods, were collected. Timings and durations of relapses were extracted. A multivariate logistic regression was used to assess the relationship between relapses and prior use of different DMTs. Results Completed data were available for 99 pregnancies (87 patients). Mean age and mean age at onset were 31.8 ± 5 and 24.4 ± 5.6 years, respectively, while the mean disease duration was 7.4 ± 4.6 years. Most pregnancies (89.9%) occurred in patients who were on DMTs in the year preceding pregnancy with a mean treatment duration of 63.4 ± 29 months. The rates of occurrence of relapses during pregnancy and postpartum were 17.2% and 13.7%, respectively. Most of the relapses occurred during the first (n = 6) and third (n = 7) trimesters. Rate of relapse was highest among patients receiving natalizumab and fingolimod before pregnancy. A longer washout period was significantly associated with relapse occurrence. Conclusion The relapse occurrence during pregnancy is higher than the previously published rates. The use of high-efficacy therapies with long washout periods before conception was associated with an increased risk of relapses during pregnancy. Postpartum relapse occurrence was similar to that in previous reports.

Collaboration


Dive into the Jasem Al-Hashel's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge